WHO: The proposal involves 40 National Funding Authorities and/or Agencies under the Umbrella of Eureka and is coordinated by the Eureka Secretariat in Brussels. Founded in 1985, Eureka is a global network, with 48 Member States plus the European Commission. It includes nearly all countries of the European continent as well as international members like Israel, Turkey, Korea, Canada, Singapore, South Africa, Argentina and Chile. The Consortium also benefits from the fact that is has successfully run the Eurostars 1 and 2 programs. WHAT: The proposed European Partnership on Innovative SMEs will comprise two main instruments (Eurostars 3 and Innowwide) as well as measures to connect to existing EU programs, initiatives and other European partnerships. EUROSTARS 3 (E*3) is an instrument that supports the international cooperation of SMEs in the field of non-military collaborative innovation projects. An E*3 project consortium must be composed of at least 2 independent entities from at least two participating countries and must be led by an innovative SME. The E*3 instrument benefits from accompanying measures that strengthen SMEs’ ability to access foreign markets like the INNOWWIDE instrument, which has already been piloted with the support of some Eureka network members in recent years. WHY: The biggest challenges for innovative SMEs are the access to international cooperation and to enter international markets as well the ability to receive funding. E*3 through its coordination of national innovation programs will in addition support the further development of a European Research Area. HOW: The Eureka Secretariat will organize two joint transnational calls per year for E*3 and one call per year for Innowwide. National Innovation Agencies actively support the implementation of E*3 via national funding and support measures as well as services to applicants and promotion of the program.

This proposal is the continuation of the Description of the Action of the Grant Agreement 101055476 signed under the European Innovation Ecosystems Work Programme 2021-2022. The proposal involves 41 National/regional Funding Bodies and/ Agencies under the umbrella of Eureka, and is coordinated by the Eureka Secretariat in Brussels. The partnership will be comprised of two main instruments(Eurostars-3 and Innowwide) as well as accompanying measures to further supports SMEs and to connect existing EU programmes, initiatives and other European partnerships. On this proposal, the consortium describes the additional activities that will take place under the EIE WP 2023-2024. The activities implemented under this Work Programme mirror to a great extent those described in the DoA.

Worldwide, nearly 47 million people are currently estimated to be living with dementia, and the number is expected to almost double every 20 years, yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 30 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative actions; since 2011, a cumulated funding of 132M€ has been dedicated to competitive transnational calls and JPND is now a reference for European and global knowledge and as an innovation platform in the area of neurodegenerative diseases. Building on earlier successes of the JPND Research Strategy in scaling-up and establishing synergies with Horizon 2020, there is a need to continue previous efforts to consolidate the JPND successes in defragmentation, better coordination and alignment amongst the countries, by developing new links with the EC. JPcofuND 2 aims at launching in 2019 an ambitious call for proposals on personalised medicine, where the benefits for the patients affected with neurodegenerative diseases will be explored through personalised diagnosis, personalised prevention and personalised care. Participating countries have earmarked 24,7 M€ of national funds for this call. Moreover, to expand the impact of the project, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.